FibroBiologics, Inc. (FBLG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

FibroBiologics, Inc. (FBLG) closed at USD 0.95 on 2026-10-14, a change of -88.7 % over the past year, with a market capitalization of USD 7.08M.

FibroBiologics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

FibroBiologics, Inc. key figures

Previous close

USD 0.95 (2026-10-14)

1-year change

-88.7 %

Market cap

USD 7.08M

Enterprise value

USD 4.61M

P/E ratio (trailing)

-0.19

P/E ratio (forward)

-0.31

EPS (trailing)

-5.22

EPS (forward)

-3.25

PEG ratio

n/a

Price to book

1.31

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.04

Employees

15

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for FibroBiologics, Inc. and compare it with other stocks.